title: Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.
abstract: Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Nine other women received spironolactone 100 mg/day for 1 year and did not have significant changes in serum androgens, but had a significant (P less than .01) 47% reduction in the Ferriman-Gallwey score (15.2 +/- 0.8 to 8 +/- 0.8). Thus, with either treatment, the reduction in Ferriman-Gallwey scores did not correlate with the change in androgen levels. The patients treated with dexamethasone for 1 year then received spironolactone 100 mg/day together with dexamethasone for an additional year. Serum androgen levels did not change further, but the Ferriman-Gallwey scores decreased significantly (P less than .01) from 11.4 +/- 0.6 to 3.74 +/- 0.7 (-61%). These data suggest that serum androgens are not helpful in assessing response to the treatment of hirsutism and that despite normal androgen levels, only modest clinical improvement may be expected with dexamethasone treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cattedra di Endocrinologia, Università di Palermo, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Carmina
authors.forename: R A
authors.initials: RA
authors.lastname: Lobo
mesh_terms: D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000097:blood*; D015113:Androstane-3,17-diol / Q000031:analogs & derivatives / Q000097:blood; D000735:Androstenedione / Q000097:blood; D000738:Androsterone / Q000031:analogs & derivatives / Q000097:blood; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D013196:Dihydrotestosterone / Q000097:blood; D004338:Drug Combinations; D005260:Female; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D004338:Drug Combinations; D013196:Dihydrotestosterone; C027927:androsterone glucuronide; C056506:androstane-3,17-diol 17-sulfate; D015113:Androstane-3,17-diol; C028895:androstane-3,17-diol glucuronide; D013148:Spironolactone; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone; D000738:Androsterone